Benzinga | Mar 2, 2021 01:42PM EST

Stifel Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $58

Stifel analyst Stephen Willey initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Buy rating and announces Price Target of $58.